CombiMatrix's SNP-Based Miscarriage Analysis Test Granted Conditional Approval From New York State Department of Health

CombiMatrix's SNP-Based Miscarriage Analysis Test Granted Conditional Approval
From New York State Department of Health

CombiMatrix Now Markets Three Prenatal and Postnatal Analysis Tests in New

IRVINE, Calif., July 31, 2014 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing
services for developmental disorders and cancer diagnostics, today announced
that its SNP-based chromosomal microarray analysis (CMA) test for miscarriage
analysis, the CombiSNP™ Array for Pregnancy Loss, or products of conception,
has received conditional approval from the New York Department of Health
(NYDOH). This approval is for testing on fresh and formalin fixed paraffin
embedded (FFPE) patient samples. Last year, the Company's CMA miscarriage
analysis test for fresh tissue was conditionally-approved by NYDOH.

Over one-half of all first trimester pregnancy losses are due to chromosomal
abnormalities. Older technologies, such as Karyotyping, are subject to
frequent cell culture failure, but microarray testing is DNA-based, and does
not require cell culturing. Unlike older microarray methodologies, the
CombiSNP™ array can identify triploidy and molar pregnancies as well. In
addition, the CombiSNP™ Array for Pregnancy Loss can use FFPE samples so the
analysis can be performed if no fresh tissue is available.

"The availability of this SNP-based CMA test provides New York physicians the
flexibility to either use fresh tissue or stored FFPE tissue when fresh tissue
is not available," said Mark McDonough, chief executive officer of
CombiMatrix. "In addition, this conditional license is the second this month,
following conditional approval to market our CombiSNP™ CMA test for pediatric
analysis, and the third since last year that we have received from the New
York Department of Health. This approval enables CombiMatrix to market both of
our CMA miscarriage analysis tests in New York state. We view these
conditional approvals as validation of our regulatory and clinical
capabilities to bring new test solutions to our customers."

Under conditional approval, CombiMatrix will be able to market the test in New
York while the test is under Clinical Laboratory Reference System review. Upon
completion of the review, either the test will receive full marketing approval
or additional information will be required in order to achieve final approval.

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and
comprehensive clinical support for the highest quality of care – specializing
in miscarriage analysis, prenatal and pediatric healthcare. CombiMatrix offers
comprehensive testing services for the detection of abnormalities of genes at
the DNA level beyond what can be identified through traditional
technologies.The Company performs genetic testing utilizing microarray, FISH,
PCR and G-Band chromosome analyses. Additional information about CombiMatrix
is available at or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995.These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change.All statements, other than
statements of historical fact included in this press release, are
forward-looking statements.Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words.These forward-looking
statements are not guarantees of future results and are subject to risks,
uncertainties and assumptions that could cause our actual results to differ
materially and adversely from those expressed in any forward-looking
statement.The risks and uncertainties referred to above include, but are not
limited to:obtaining full approval from the NYDOH to sell SNP-based
miscarriage analysis tests in New York State; market acceptance of CMA as a
preferred method over karyotyping; the rate of transition to CMA from
karyotyping; our ability to successfully expand the base of our customers and
strategic partners, add to the menu of our diagnostic tests in both of our
primary markets, develop and introduce new tests and related reports, optimize
the reimbursements received for our testing services, and increase operating
margins by improving overall productivity and expanding sales volumes; our
ability to successfully accelerate sales, allow access to samples earlier in
the testing continuum, steadily increase the size of our customer rosters in
both developmental medicine and oncology; our ability to attract and retain a
qualified sales force; rapid technological change in our markets; changes in
demand for our future products; legislative, regulatory and competitive
developments; general economic conditions; and various other factors.Further
information on potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q,
and in other filings with the Securities and Exchange Commission.We undertake
no obligation to revise or update publicly any forward-looking statements for
any reason, except as required by law.

CONTACT: Company Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
         Investor Relations Contact:
         Robert Flamm, Ph.D.
         Russo Partners LLC
         Tel (212) 845-4266
         Media Contact:
         David Schull or Lena Evans
         Russo Partners LLC
         Tel (212) 845-4271

CombiMatrix Corporation
Press spacebar to pause and continue. Press esc to stop.